This technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer
HCS main assets for active cosmetic ingredients
Confirming the efficacy of nutraceuticals and functional food is a key for the development of new compounds. High content in vitro assays play a role in researching and developing new actives ingredients dedicated to human and animals food.
Phenotypic screening by High Content Screening allows analysing toxic events, as genotoxicity, hepatotoxicity, neurotoxicity or cardiotoxicity at the early stage of research.
BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
To ensure personalised treatment for familial hypercholesterolemia
A holistic approach to address brain delivery
Face to the high failure of drug candidate in clinical trial, in particular involving the brain, we goal to develop more relevant and more predictive in vitro models for preclinical assessment, in the aim to early select molecules of interest, in term of efficacy and safety.
To design and industrialize new pharmacological in vitro assays for the screening of compounds/biopharmaceuticals in 3D
To develop the technological platform to produce lab-grown meats. The project is funded by EUREKA and the national funding agencies associated with the Eurostars program.
To develop a universal “plug-and-play” liver-on-chip platform mimicking the major events occurring in the liver sinusoid in order to predict the hepatoxicity of drugs.
Stage assistant ingénieur (~ niveau m1) prévu du 1er septembre 2020 au 12 février 2021 (6 mois) La société HCS Pharma (Loos, France) recherche un stagiaire de master 1 pour fin 2020. La personne recrutée Read more…
As we are involved in some very interesting projects, we have the chance to work with amazing specialists in many field. All these people help us to make the BIOMIMESYS® technology better, easier to use Read more…
Dear all, We hope this email finds you, your family and colleagues well! We are available to discuss with you:– about your needs in high content screening/analysis services. We would be happy to organise videoconferences Read more…
Our BIOMIMESYS® products are now available in the Dominique Dutscher’s catalogue. We are very happy to work with such a famous company ! Founded in 1982 in Alsace (France) Dominique Dutscher SAS is specialized in Read more…
The brain extracellular matrix (ECM) has a specific composition. Contrary to other organs, this ECM contains a low level of fibrous proteins, like collagen and fibronectin. Actually it is mainly composed of proteoglycans, which are Read more…
Clinicians and researchers worldwide are actively studying the mechanisms governing the infection of humans by SARS-CoV-2 and its consequences on their health, with the objective is to find effective therapies. We all aknowledge their important Read more…
Immersive technologies (XR) are playing an increasingly important role in many areas of the healthcare sector. In HCS Pharma we monitor this progress and we have used these technologies many times, for example at the Read more…
Elisa Moya started her bachelor’s degree in 2013, in Biological Sciences, at the University of Granada, Spain. During her career period, in 2015, she studied one year in Portugal (Erasmus+). Moreover, in the summer 2016, Read more…
The extracellular matrix (ECM) is composed of macromolecules surrounding the cells. They interact with each other and with the cells, cross-link and polymerize, ensuring the maintenance and the function of organs. The primary role of Read more…
Dr. Karine Hannebicque has joined our Scientific Advisory Board. She is a surgeon in breast cancer and reconstructive surgery working in Oscar Lambret Center in the Department of breast oncology since 2013. She is also Read more…
We are really happy to welcome Prof. Lo in our Scientific Advisory Board. Prof. Lo has a huge experiment in hepatitis infection and liver diseases with more than 120 publications in this field. With help Read more…
As part of the validation of her Master’s degree in biotechnology (University of Lille), specializing in cellular and molecular engineering, Elise recently joined HCS Pharma. After having completed three internships from one to four months Read more…
Just before Covid-19 pandemic crisis widely spread to France, we attended the User Meeting organized by Molecular Devices in Hilton Garden Inn Leiden (Oegstgeest, Netherlands). We enjoyed the programme, gathering a variety of topics but Read more…
As many companies in France and in the world, the COVID-19 pandemic deeply affects our activities. For safety reasons, most of our work is now done remotely but we maintain essential activity in laboratories to Read more…
Présentation de l’entreprise HCS Pharma est une start-up biotechnologique spécialisée en imagerie cellulaire pour le criblage et l’étude de l’efficacité ou la toxicité de molécules d’intérêt pharmaceutique, cosmétique ou agroalimentaire. Nous développons pour cela nos Read more…
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.